Join to View Full Profile
600 Highland Ave# K6Madison, WI 53792
Phone+1 608-265-8690
Fax+1 608-265-8133
Dr. Fletcher is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Christopher Fletcher is an oncologist in Madison, WI and is affiliated with multiple hospitals in the area, including William S. Middleton Memorial Veterans Hospital and University of Wisconsin Hospitals and Clinics. He received his medical degree from Loyola University Chicago Stritch School of Medicine and has been in practice 10 years. He specializes in hematologic oncology and is experienced in hematologic oncology, hodgkin's lymphoma, multiple myeloma, lymphoma, and b-cell chronic lymphocytic leukemia.
Education & Training
University of Wisconsin Hospitals and ClinicsFellowship, Hematology and Medical Oncology, 2011 - 2014- University of Wisconsin Hospitals and ClinicsResidency, Internal Medicine, 2007 - 2010
Loyola University Chicago Stritch School of MedicineClass of 2007
Certifications & Licensure
WI State Medical License 2009 - 2025
American Board of Internal Medicine Hematology- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Phase II study of venetoclax added to bendamustine and obinutuzumab in patients with high-risk follicular lymphoma as front-line therapy: PrE0403.Craig A Portell, Opeyemi A Jegede, Nina Wagner-Johnston, Grzegorz S Nowakowski, Christopher Fletcher
Blood Cancer Journal. 2025-05-12 - Measurable Residual Disease Testing Following Nonintensive Chemoimmunotherapy is Predictive of Need for Maintenance Therapy in Previously Untreated Mantle Cell Lymphom...Julie E Chang, Danielle McQuinn, Meredith Hyun, KyungMann Kim, Vaishalee P Kenkre
Clinical Lymphoma, Myeloma & Leukemia. 2025-03-01 - Maintenance low-dose fixed duration lenalidomide and rituximab following bendamustine and rituximab induction in previously untreated chronic lymphocytic leukemia and ...Julie E Chang, Tuo Wang, KyungMann Kim, Matthew Folstad, Mariah Endres
Leukemia & Lymphoma. 2024-10-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
